Background: Dialysis patients and transplant recipients, especially those with acquired cystic kidney disease, are at increased risk for renal cell carcinoma (RCC). We report our experience in 15 posttransplant patients who underwent nephrectomy for renal masses.
Methods: Institutional review board-exempt retrospective chart review was performed on 15 transplant recipients who subsequently underwent native nephrectomy for masses.
Results: A total of 22 renal units were removed from 15 patients, with 18 kidneys removed laparoscopically and 4 via an open approach. Of those 22 kidneys, 17 units (77%) from 13 patients contained RCC. One kidney had two cancers, for a total of 18 cancers. The distribution of RCC is as follows: 11 papillary, 4 clear cell, and 3 chromophobe. Ten patients were stage T1N0M0, two patients were stage T2N0M0, and one was stage T3N0M0. No patients had immunosuppression withheld. The average length of stay for laparoscopic nephrectomy was 95 hr, with a median length of stay of 61 hr (range 33-360 hr). Surgical complications (7%) included a delayed extraction site hernia. There were no episodes of rejection, dialysis, or injury to the kidney. One patient developed pulmonary metastasis. Average follow-up and metastasis-free survival was 60.6 and 58.4 months, respectively.
Conclusions: Renal transplant recipients with suspicious masses or cancer or both can safely undergo native nephrectomy without jeopardizing their grafts by stopping immunosuppression. Immunosuppression does not seem to promote metastasis or recurrence, although longer follow-up is required. As in patients on hemodialysis, papillary RCC is more common than clear cell carcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TP.0b013e31821ab97a | DOI Listing |
Blood Transfus
December 2024
National Blood Centre, Istituto Superiore di Sanità, Rome, Italy.
Parvovirus B19 (B19V) presents a significant concern in the context of blood transfusion safety, given its potential for transmission through contaminated blood products, and the increased viral circulation recently reported across Europe. This study examines the recent epidemiological trends of B19V in Italy, where a notable increase in B19V-positive plasma units was observed during early 2024. While routine NAT testing for B19V in individual blood donations is not currently justified, the existing screening protocols for plasma intended for industrial fractionation are crucial to ensure the safety of plasma-derived medicinal products.
View Article and Find Full Text PDFBlood Cancer Discov
January 2025
Princess Máxima Center, Utrecht, Netherlands.
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. Here, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 non-transplanted controls. CH was detected in 16% of HCT recipients and 8% of controls, at variant allele frequencies (VAFs) of 0.
View Article and Find Full Text PDFClin Exp Nephrol
January 2025
Division of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Background: This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.
Methods: FCGR3A 158F/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021.
Introduction: Prior studies have demonstrated racial disparities in access to liver transplantation but determinants of these disparities remain poorly understood. We used geographic catchment areas for transplant centers (transplant referral regions, TRRs) to characterize transplant environment contributors to racial and ethnic disparities in liver transplant access.
Methods: Data were obtained from the Scientific Registry for Transplant Recipients (SRTR) and the National Center for Health Statistics (NCHS) from 2015 to 2021.
Intern Med J
January 2025
Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Background: Access to liver transplantation (LT) is affected by geographic disparities. Higher waitlist mortality is observed in patients residing farther from LT centres, but the impact of distance on post-LT outcomes is unclear.
Aims: To evaluate whether the distance LT recipients reside from their LT centre affects graft and patient outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!